Methotrexate
Juvenile Idiopathic Arthritis
National Institute of Allergy and Infectious Diseases (NIAID)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
13 Active assets in the Juvenile Idiopathic Arthritis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivestim Paul Szabolcs | Phase 2 | CCC |
Melphalan Paul Szabolcs | Phase 2 | CCC |
Thiotepa Paul Szabolcs | Phase 2 | CCC |
Jnj-78436735 National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | CCC |
Monovalent [B.1.351] Cov2 Pres Dtm-As03 National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | CCC |
View all 18 →
Same molecule, other indications
Methotrexate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →